| Document |
Document Title |
|
WO/2023/217119A1 |
Disclosed herein is a diclofenac prodrug represented by formula (I), wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed is a method for alleviating arthritis, which inclu...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/208005A1 |
Compounds of formula (I), formula (II) or formula (III), the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of diseases or disorders are provided.
|
|
WO/2023/208170A1 |
Provided are a protease inhibitor, a method for preparing same, and use thereof. The protease inhibitor can be combined with one or more pharmaceutically acceptable excipients or one or more other active ingredients to be used as a PLpro...
|
|
WO/2023/205450A1 |
Provided herein are compounds, compositions, and methods for rapid isolation of nucleic acids from a sample.
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/186881A1 |
The invention relates to p38 MAP kinase inhibitors of formula (I) as shown in the description for use in the treatment of colorectal cancer. Further, the invention relates to p38 MAP kinase inhibitors specifically mentioned in the descri...
|
|
WO/2023/178035A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/177845A1 |
Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the f...
|
|
WO/2023/173053A1 |
The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.
|
|
WO/2023/171801A1 |
Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentia...
|
|
WO/2023/171665A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/163533A1 |
The present invention relates to a pure organic molecule (without a metal center) and a use of the pure organic molecule as an emitter or absorber in an optoelectronic device. According to the present invention, the pure organic molecule...
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/149548A1 |
The present invention addresses the problem of providing a novel pharmaceutical composition, and in particular, a novel anti-cancer pharmaceutical composition, and a novel compound used in said pharmaceutical composition. The present i...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143386A1 |
The present invention relates to an aromatic ring-fused heterocyclic ring compound as a potassium channel regulator, and the preparation therefor and the use thereof. Specifically, the compound of the present invention has a structure as...
|
|
WO/2023/146975A1 |
Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a co...
|
|
WO/2023/144228A1 |
The present invention relates to a copolymer having several azide functionalities that can be prepared by cationic ring opening polymerisation. The copolymer comprises a first monomer unit and a second monomer unit which are different fr...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/099462A1 |
The present invention relates to amine-containing vinyldisiloxane compounds which are useful in the manufacture of elastomeric polymers that can be used in rubber articles such as tires. The present invention further relates to a process...
|
|
WO/2023/098882A1 |
Provided herein are diastereomer-selective synthetic methods and intermediates for making chiral 3, 5-disubstituted morpholine compounds, which are useful for the preparation of compounds useful as mitochondrial-derived activator of casp...
|
|
WO/2023/096387A1 |
The present invention relates to an organic light-emitting compound represented by [chemical formula A] or [chemical formula B], which can be used in an organic light-emitting device, and an organic light-emitting device comprising same,...
|
|
WO/2023/088229A1 |
Provided in the present invention is a method for synthesizing rivaroxaban. The method comprises: reacting an intermediate I and an intermediate II in an organic solvent in the presence of an alkali to obtain rivaroxaban, wherein the syn...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/091565A1 |
The current invention relates to nuclear receptor-binding SET domain-containing 2 (NSD2)- targeted protein degradation reagents and pharmaceutical compositions thereof and their utility as anti- cancer agents.
|
|
WO/2023/079128A1 |
The invention provides a process for manufacturing an aniline (2), wherein PG denotes hydrogen or an amino protective group, that is suitable for large-scale manufacturing of said aniline (2).
|
|
WO/2023/079569A1 |
The present disclosure provides a process for preparing a compound of Formula I, the process comprising: a. mixing a compound of Formula II with a compound of Formula III in a mole ratio range of 1:1 to 1.3:1 to obtain a first mixture; b...
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/078392A1 |
Provided are a 2-(aryl-2-yl) morpholine and a deuterated derivative thereof, a preparation method therefor and an application thereof. In particular, involved are the use of a compound shown by general formula (V) in the treatment of cen...
|
|
WO/2023/074527A1 |
The present invention addresses the problem of providing: a crystalline composition comprising a benzoxazine compound represented by general formula (1); and a method for producing same. As a solution, provided is a crystalline compositi...
|
|
WO/2023/066357A1 |
The present disclosure relates to fused cyclic compounds, preparation methods therefor, and medical uses thereof. Specifically, the present disclosure relates to the fused cyclic compound represented by general formula (I), a preparation...
|
|
WO/2023/064196A1 |
The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or proph...
|
|
WO/2023/051716A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inh...
|
|
WO/2023/055763A2 |
Treatment of CHD1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers using CHD1L inhibitors. Small molecule inhibitors of CHDL1 which inhibit CHD1L ATPase and inhibit CHD1L-dependent TCF-transcription have...
|
|
WO/2023/044364A1 |
The present invention relates to protoporphyrinogen oxidase inhibitors of the general formula (I) where the variables are defined herein. The invention features processes and intermediates for preparing the benzoxazinones of formula (I),...
|
|
WO/2023/037818A1 |
The present invention addresses the problem of providing a means with which it is possible to inhibit a volatile component (sulfur-containing volatile component) which has an odor generated during production of a cured product by means o...
|
|
WO/2023/030434A1 |
An inhibitor of a prostate specific membrane antigen and a pharmaceutical use thereof. Specifically, the present solution belongs to the field of radiopharmaceuticals and relates to a compound represented by formula (IV) or a pharmaceuti...
|
|
WO/2023/034786A1 |
The disclosure provides processes for preparing Compound A, Compound E, Compound I, salts thereof, and/or stereoisomers thereof, as described herein.
|
|
WO/2023/026850A1 |
The present invention addresses the problem of providing: a novel benzoxazine compound which has excellent heat resistance, and is able to be cured under low-temperature conditions; a resin starting material composition which contains th...
|
|
WO/2023/021328A1 |
The current application relates to processes and intermediates thereof for the preparation of (S)-4-(3-(4-(tert-butoxycarbonyl)morpholin-2- yl)propanoyl)-3,5-difluorobenzoic acid (Compound 1A), a key synthetic intermediate in the synthes...
|
|
WO/2023/009204A1 |
Benzoxazine compounds represented by structures set forth herein; benzoxazine resins including same, hardenable resin compositions including benzoxazine resin described herein; hardenable resin compositions including at least one photoha...
|
|
WO/2023/280638A1 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X" of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2023/281421A1 |
Hydrofluoroolefin amine compounds are represented by the following general formula (I): 5 (Rf 2-)(Rf 3CF2-)N-CH=CF-Rf 1 Formula I where Rf 1 is a linear, branched, or cyclic fluoroalkyl group containing 1-5 carbon atoms and may contain u...
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2023/278874A1 |
Provided herein are libraries of nerve-specific fluorescent contrast agents of substituted 8-methyl-phenoxazine compounds of Formula (I) with excitation and emission profile comparable to US FDA approved methylene blue (MB) and indocyani...
|
